The next focusIR Investor Webinar takes places on 14th May with guest speakers from Blue Whale Growth Fund, Taseko Mines, Kavango Resources and CQS Natural Resources fund. Please register here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksGooch & Housego Regulatory News (GHH)

Share Price Information for Gooch & Housego (GHH)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 562.00
Bid: 560.00
Ask: 568.00
Change: 12.00 (2.18%)
Spread: 8.00 (1.429%)
Open: 560.00
High: 562.00
Low: 550.00
Prev. Close: 562.00
GHH Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

AGM Trading Update

21 Feb 2024 07:00

RNS Number : 8339D
Gooch & Housego PLC
21 February 2024
 

This announcement contains inside information as stipulated under the UK version of the Market Abuse Regulation (EU no. 596/2014) as it forms part of UK law by virtue of the European Union (Withdrawal) Act 2018 (as amended from time to time).

 

 

21 February 2024

 

Gooch & Housego PLC

("G&H" or the "Company" or the "Group")

 

AGM Trading Update

 

"Further order book growth but near-term demand impacted by destocking"

 

 

Gooch & Housego PLC (AIM: GHH), the specialist manufacturer of photonic components & systems, will hold its Annual General Meeting at 11.00 a.m. today at the Company's headquarters in Ilminster, Somerset.

 

In the first four months of the financial year the Group's order book has increased to £128.5m (September 2023: £124.1m) supported by strong intake from our medical diagnostic customers and new orders for our armoured vehicle periscope systems. We have also secured an important new customer in the sub-sea data communications market which will ramp-up to support revenues in the second half of FY2024.

 

The Group has made further progress in implementing operational improvements in its production facilities and has continued to reduce lead times offered to customers. We are delivering on our strategy of transferring additional product lines to our lower cost contract manufacturing partners which will support greater operational capacity and flexibility as well as some medium-term margin expansion.

 

As previously stated, some of our customers in the Industrial and Medical laser markets have been reducing their inventory holdings and reporting near term demand weakness from some end markets. This period of inventory adjustment is proving to be deeper and more prolonged than previously anticipated. Our semiconductor market customers have reduced near-term demand but still expect strong growth in the medium term. We have also received customer notification that certain US A&D programmes will no longer go ahead or have been deferred.

 

As a result, the Group's trading for FY2024 is expected to be more weighted to the second half and profit growth for the full year to be lower. Adjusted profit before tax is anticipated to be circa £3 million below management's previous expectations.

 

Given the strong medium term customer demand demonstrated by a growing order book, recent operational improvements and the Group's strategic focus, we believe we remain extremely well placed to respond quickly and benefit as several key end markets recover.

 

Strategy Update

 

The Group is executing against the recently communicated strategic objectives and is making strong progress. The build out of the production and R&D facilities at our new US medical diagnostics hub located within the GS Optics campus in Rochester, NY is progressing well. We have secured our first customer order for our US R&D team at the facility and are in discussions with a number of other Life Sciences customers for further R&D and production orders to be supplied from the facility. Our review of the Group's product portfolio is well advanced and near-term actions in this area are expected to support the future profit margin improvement of the Group, especially in our A&D business.

 

The integration of the recently acquired GS Optics and Artemis businesses within the Group is well advanced. The commercial synergies anticipated from the combination of our precision optics capabilities with Artemis' thin film coating services has been confirmed by some recent new contract awards and further large orders are being pursued. Whilst in the near-term GS Optics is impacted by the slowdown in demand from destocking by some of its Industrial market customers, we have received significant levels of interest from the Group's customers in our new polymer optics capabilities.

 

The Group's financial position remains strong. Working capital levels have been reduced in the first four months of the financial year and net debt at the end of January 2024 stood at £30.5m (Sept 2023: £31.7m).

 

Charlie Peppiatt, Chief Executive Officer of Gooch and Housego, commented:

"Whilst we are pleased with the order book growth, reduction in lead times and strategic progress, the Group's performance is likely to be impacted in the near term by market dynamics. Nonetheless, we remain focused on executing on our strategic objectives and our improved customer service has been recognised with important new orders from both existing and new customers.

"Our review of the Group's product portfolio is nearing completion. This will be an important contributor in improving the profitability of the Group, especially in our A&D business.

"G&H is well positioned in structural growth markets and is executing on its strategic plan that will deliver sustainable margin growth for the Group."

For further information please contact:

 

Charlie Peppiatt, Chief Executive Officer

Chris Jewell, Chief Financial Officer 

Gooch & Housego PLC

+44 (0) 1460 256440

 

Mark Court / Sophie Wills / Abigail Gilchrist

G&H@buchanan.uk.com

Buchanan

+44 (0) 20 7466 5000

 

Christopher Baird / David Anderson

Investec Bank plc

+44 (0) 20 7597 5970

 

 

Notes to editors

 

1. Gooch & Housego is a photonics technology business headquartered in Ilminster, Somerset, UK with operations in the USA and Europe. A world leader in its field, the company researches, designs, engineers and manufactures advanced photonic systems, components and instrumentation for applications in the Aerospace & Defence, Industrial, Life Sciences and Scientific Research sectors. World leading design, development and manufacturing expertise is offered across a broad range of complementary technologies.

 

2. All financial information included in this announcement is sourced from unaudited management accounts and excludes any specific items. This announcement contains certain forward-looking statements that are based on management's current expectations or beliefs as well as assumptions about future events. These are subject to risk factors associated with, amongst other things, the economic and business circumstances occurring from time to time in the countries and sectors in which G&H operates. It is believed that the expectations reflected in these statements are reasonable but they may be affected by a wide range of variables which could cause actual results, and G&H's plans and objectives, to differ materially from those currently anticipated or implied in the forward-looking statements. Investors should not place undue reliance on any such statements. Nothing in this announcement should be construed as a profit forecast.

 

The person responsible for arranging the release of this announcement on behalf of the Company is Chris Jewell, Chief Financial Officer.

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
MSCPPUQUPUPCGBU
Date   Source Headline
26th Aug 20221:00 pmRNSDirector/PDMR Shareholding
19th Aug 202212:24 pmRNSNotification of Major Holdings
19th Aug 202212:19 pmRNSNotification of Major Holdings
17th Aug 202212:00 pmRNSDirector/PDMR Shareholding
17th Aug 202211:57 amRNSDirector/PDMR Shareholding
17th Aug 202211:54 amRNSDirector/PDMR Shareholding
17th Aug 20227:00 amRNSTrading Update and Directorate Changes
13th Jun 202212:58 pmRNSHolding(s) in Company
7th Jun 20227:00 amRNSInterim Results
23rd May 20224:41 pmRNSSecond Price Monitoring Extn
23rd May 20224:36 pmRNSPrice Monitoring Extension
11th May 20227:00 amRNSNotification of Half Year Results
5th Apr 20227:00 amRNSHalf Year Trading Update
23rd Feb 20221:11 pmRNSResult of AGM
23rd Feb 20227:00 amRNSAGM Trading Update
9th Feb 20224:35 pmRNSPrice Monitoring Extension
13th Jan 20227:00 amRNSGrant of LTIP Awards
12th Jan 202212:18 pmRNSHolding(s) in Company
30th Dec 20214:41 pmRNSSecond Price Monitoring Extn
30th Dec 20214:36 pmRNSPrice Monitoring Extension
17th Dec 20217:00 amRNSPosting of Annual Report and AGM Notice
30th Nov 20217:00 amRNSResults for the year ended 30 September 2021
17th Nov 20217:00 amRNSNotification of Full Year Results
25th Oct 20214:41 pmRNSSecond Price Monitoring Extn
25th Oct 20214:35 pmRNSPrice Monitoring Extension
5th Oct 20217:00 amRNSFull Year Trading Update
18th Aug 20217:00 amRNSDiversity Underpins Competitive Advantage
27th Jul 202112:20 pmRNSUpdate on 2021 AGM Resolutions
9th Jun 20213:58 pmRNSPosting of Interim Report
3rd Jun 20217:00 amRNSHolding(s) in Company
1st Jun 20217:00 amRNSInterim Results
10th May 20217:00 amRNSNotification of Half Year Results
28th Apr 20213:20 pmRNSHolding(s) in Company
7th Apr 20217:00 amRNSHalf Year Trading Update
26th Mar 20217:00 amRNSGrant of SAYE Options
12th Mar 20217:00 amRNSAppointment of Non-Executive Director
11th Mar 20214:59 pmRNSPCA to the Chairman Share Purchase
24th Feb 20211:01 pmRNSResult of AGM
24th Feb 20217:00 amRNSAGM Trading Update
8th Feb 202110:20 amRNSHolding(s) in Company
22nd Jan 20214:40 pmRNSSecond Price Monitoring Extn
22nd Jan 20214:35 pmRNSPrice Monitoring Extension
7th Jan 202112:17 pmRNSGrant of LTIP Awards
23rd Dec 20207:00 amRNSLaunch of Satellite Laser Communication System
18th Dec 20207:00 amRNSPosting of Annual Report and AGM Notice
1st Dec 20207:00 amRNSPreliminary Results
16th Nov 20207:00 amRNSNotification of Full Year Results
6th Oct 20207:00 amRNSFull Year Trading Update
2nd Sep 20207:00 amRNSTrading Update
1st Sep 202012:07 pmRNSSecond Price Monitoring Extn

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.